A
Agilent Technologies, Inc.
A's fundamentals are strong: it turned 17% of its revenue into free cash flow and revenue grew 8.6%. At 34x earnings, it's trading in line with its usual 32x. Analysts expect earnings growth.
A Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Healthy |
A's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
A PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 26x | $173 | — |
| Cheap | 28x | $141 | -19% |
| Fair | 31x | $160 | -7.6% |
| Current | 34x | $173 | — |
| Expensive | 45x | $227 | +31% |
Historical ranges are pointers, not guarantees.
A's PE is in its fair range at 34x. If earnings grow as analysts expect, today's price would be 26x next year's earnings, in its cheap range.
A Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for A, with profitability improving.
A Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.70 | +32% |
| Q3 2026 | $5.08 | +19% |
| Q2 2026 | $4.98 | +23% |
| Q1 2026 | $4.53 | +3.9% |
| Q4 2025 | $4.57 | +3.2% |
| Q3 2025 | $4.27 | -11% |
| Q2 2025 | $4.06 | -3.6% |
| Q1 2025 | $4.36 | +4.3% |
| Q4 2024 | $4.43 | +5.7% |
A earned $5.08 per share over the past year, up 19% from the year before.
A Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.9B | +8.1% |
| Q2 2026 | $1.8B | +10% |
| Q1 2026 | $1.8B | +7% |
| Q4 2025 | $1.9B | +9.4% |
| Q3 2025 | $1.7B | +10% |
| Q2 2025 | $1.7B | +6% |
| Q1 2025 | $1.7B | +1.4% |
| Q4 2024 | $1.7B | +0.8% |
A's revenue has grown year over year for eight quarters in a row: $1.9B last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | +2.9 points |
| Q2 2026 | 22% | +3.8 points |
| Q1 2026 | 20% | -2.7 points |
| Q4 2025 | 24% | -0.2 points |
| Q3 2025 | 21% | -0.4 points |
| Q2 2025 | 18% | -5.1 points |
| Q1 2025 | 22% | -0.8 points |
| Q4 2024 | 24% | -0.2 points |
A's operating margin was 24% last quarter, up 2.9 points from the same quarter a year ago.
A Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $439M | +69% |
| Q2 2026 | $201M | +88% |
| Q1 2026 | $175M | -48% |
| Q4 2025 | $452M | +16% |
| Q3 2025 | $259M | -28% |
| Q2 2025 | $107M | -53% |
| Q1 2025 | $334M | -15% |
| Q4 2024 | $388M | -10% |
A generated $1.3B in free cash flow over the past year, up 16% from the year before.
A Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | -0.7% | -2M shares |
| 3 years | -4.1% | -12M shares |
| 5 years | -7.5% | -23M shares |
| Available history | -11% | -35M shares |
A has 283M diluted shares, down 0.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $78M |
| Q2 2026 | $65M |
| Q1 2026 | $152M |
| Q4 2025 | $85M |
| Q3 2025 | $85M |
| Q2 2025 | $165M |
| Q1 2025 | $90M |
| Q4 2024 | $335M |
A spent $380M buying back its own shares over the past year, down 44% from the year before.
A Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 0.8x | Very low |
| Q1 2026 | 0.9x | Very low |
| Q4 2025 | 0.9x | Very low |
| Q3 2025 | 1.1x | Healthy |
| Q2 2025 | 1.2x | Healthy |
| Q1 2025 | 1.1x | Healthy |
| Q4 2024 | 1.2x | Healthy |
A's net debt is about 1.1 years of its operating earnings (EBITDA), about the same as a year ago.
A Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 67.7 | Neutral |
| Stochastic | 80.4 | Overbought |
A's weekly RSI is 68 (neutral) and its Stochastic is 80 (overbought).
A PE vs Healthcare Sector
| Metric | A | Sector median | Relative |
|---|---|---|---|
| PE | 34x | 26x | 32% above |
| PE % | 65 | 29 | 36 pts above |
A is trading at 34x earnings, a 32% premium to the Healthcare sector's median of 26x.
A Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $172.5 | 0.3% above |
| 20 week MA | $155.7 | 11% above |
| 50 week MA | $138.1 | 25% above |
| 100 week MA | $132.5 | 31% above |
| 200 week MA | $132.5 | 31% above |
A has climbed back above all five of its weekly moving averages, and it's now 31% above its 200-week average.
A Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $85.4 | $117.3 | +37% |
| 2021 | $117.3 | $157.8 | +35% |
| 2022 | $157.8 | $149.2 | -5.4% |
| 2023 | $149.2 | $139.0 | -6.8% |
| 2024 | $139.0 | $135.5 | -2.5% |
| 2025 | $135.5 | $138.4 | +2.1% |
| 2026 YTD | $138.4 | $173.0 | +25% |
A has finished lower in three of the last six years. It's up 25% so far in 2026.